Vericel Corporation reported a significant increase in its financial performance for the fiscal year ended December 31, 2025, with total revenue reaching $276.3 million, a 16.5% increase from $237.2 million in 2024. The growth was primarily driven by a 21.4% rise in sales of its MACI product, which generated $239.5 million, while NexoBrid also saw a notable increase of 42.4% to $4.7 million. However, sales of Epicel decreased by 12.4% to $32.1 million. The company achieved a net income of $16.5 million, compared to $10.4 million in the previous year, marking a 59.4% increase in profitability.
In terms of operational developments, Vericel expanded its sales force by approximately 30% in late 2025, which is expected to enhance its market reach. The company also launched MACI Arthro, a new arthroscopic delivery system for MACI, which became commercially available in the U.S. during the third quarter of 2024. This product has already attracted interest from over 900 surgeons who participated in training programs, indicating a strong potential for increased adoption and market penetration. Additionally, Vericel is focusing on expanding MACI's indications to include treatment for cartilage defects in the ankle, with a clinical trial (MASCOT) initiated in late 2025.
Vericel's manufacturing capabilities are also evolving, with the completion of a new facility in Burlington, Massachusetts, which is expected to become the primary manufacturing site for MACI and Epicel once validated. The company has renewed its long-term supply agreement with Matricel GmbH for the supply of collagen membranes used in MACI, ensuring a steady supply chain through 2030. As of December 31, 2025, Vericel employed approximately 398 full-time employees, reflecting its commitment to scaling operations to meet growing demand.
Looking ahead, Vericel's management expressed optimism about future growth, particularly with the anticipated expansion of MACI into international markets, including the United Kingdom, where commercialization is expected in 2027. The company is also focused on maintaining profitability while navigating potential challenges such as regulatory approvals, market competition, and economic conditions. The ongoing geopolitical tensions and inflationary pressures are factors that could impact Vericel's operations and financial performance, but the company believes its current cash reserves and operational strategies will support its growth objectives in the near term.
About Vericel Corp
Vericel Corporation is a biopharmaceutical company specializing in advanced cell therapies for sports medicine and severe burn care. Its core products include FDA-approved autologous cell therapies MACI and Epicel, and the biologic NexoBrid licensed from MediWound. The company develops innovative biologic and tissue engineering solutions, serving orthopedic and burn treatment markets in the U.S., with a focus on improving patient outcomes and expanding minimally invasive procedures.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.